On March 11th, Congress passed a $1.5 trillion Fiscal Year (FY) 2022 omnibus appropriations package. The package reflects the impact and importance of advocacy by the clinical and translational science community, and once again provides meaningful funding increases for key programs. Specifically, the FY 2022 omnibus appropriations package provides:

• $44.96 billion for the National Institutes of Health (NIH), an increase of $2.03 billion over FY 2021.
  •  $882.27 million for the National Center for Advancing Translational Sciences (NCATS), an increase of $26.84 million over FY 2021.
    • $606.65 million for the Clinical and Translational Science Awards (CTSA) program, an increase of $19.81 million over FY 2021.
  • $3.09 billion for the National Institute of General Medical Sciences (NIGMS), an increase of $100.96 million over FY 202.
    • $410.45 million for the Institutional Development Awards (IDeA) program, an increase of $13.38 million over FY 2021.
  • $459.06 million for the National Institute on Minority Health and Health Disparities (NIMHD), an increase of $68.19 million over FY 2021 (including an increase for the Research Centers in Minority Institutions program).
  •  $2.62 billion for the Office of the NIH Director, an increase of $205.41 million over FY 2021, including $657.4 million for the Common Fund, an increase of $21.46 million over FY 2021.
•  $1 billion to establish the Advanced Research Projects Agency for Health (ARPA-H) within the HHS Office of the Secretary. Permanent placement of ARPA-H will be decided later.
• $350.4 million for the Agency for Healthcare Research and Quality (AHRQ), an increase of $12.4 million over FY 2021.

With the five-month delay in finalizing FY 2022 appropriations, the FY 2023 process is already underway on Capitol Hill. CCTS looks forward to continuing to educate congress about the value and importance of the full spectrum of medical research and hopes to working with local community advocates across the country to support the annual request for additional funding.